The small molecule drug ZD6126 selectively targets the vasculature upon which the growth of solid tumours depends. The compound has demonstrated biological "proof-of-principle" in Phase I and early Phase II studies, inducing rapid and sustained tumour blood flow shutdown in the clinic at well-tolerated doses. Preclinically this degree of shutdown leads to tumour necrosis and inhibition of tumour growth. ZD6126 has activity as a single agent and is particularly effective when used in combination with radiotherapy and/or chemotherapy. Encouraged by these and other findings, we are now seeking a partner with whom to reinitiate Phase II clinical trials.
While there are several vascular disrupting agents (VDA) in development, ZD6126 is considered by some to be "best in class" and with large quantities of material available and a strong development plan in place, the opportunity to be first to market remains a realistic possibility.
For further information, please contact Dr. Peter Davis using the form on the left.